| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.kimiabiosciences.com | |
| Market Cap | 186.41 Cr. | |
| Enterprise Value(EV) | 228.88 Cr. | 2022-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | -0.52 | Trailing Twelve Months Ending 2022-09 |
| Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2022-09 |
| Industry PE | 30.86 | Trailing Twelve Months Ending 2022-09 |
| Book Value / Share | 3.20 | Trailing Twelve Months Ending 2022-09 |
| Price to Book Value | 12.29 | Calculated using Price: 39.40 |
| Dividend Yield | 0.00 | Period Ending 2022-03 |
| No. of Shares Subscribed | 4.73 Cr. | 47,312,741 Shares |
| FaceValue | 1 | |
| Company Profile | ||
| The company is a pharmaceutical company and the state of the art manufacturing facility is manufacturing latest Bulk Drugs and intermediates (R&D based) for India and Overseas markets. | ||
| 1 Day |
|
+5.00% |
| 1 Week |
|
+3.91% |
| 1 Month |
|
-6.56% |
| 3 Month |
|
-11.33% |
| 6 Month |
|
-3.86% |
| 1 Year |
|
-12.31% |
| 2 Year |
|
-12.69% |
| 5 Year |
|
-22.60% |
| 10 Year |
|
| 9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
| Return on Equity (%) | -34.59 | -166.09 | 243.83 | 16.47 | 32.19 | -22.22 | ||||
| Return on Capital Employed (%) | -23.86 | -135.77 | -216.82 | -18.30 | 11.83 | 16.94 | 8.94 | 16.13 | -2.32 | |
| Return on Assets (%) | -13.60 | -33.62 | -92.83 | -11.72 | 4.76 | 6.24 | 1.83 | 5.31 | -3.44 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
| Shh. Funds | 2 | 0 | -4 | -5 | 2 | 6 | 13 | 18 | 15 | 15 | |
| Non Curr. Liab. | 1 | 1 | 7 | 9 | 25 | 29 | 34 | 37 | 32 | 34 | |
| Curr. Liab. | 2 | 3 | 1 | 7 | 31 | 30 | 39 | 51 | 62 | 76 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 6 | 5 | 4 | 12 | 58 | 65 | 86 | 107 | 109 | 125 | |
| Non Curr. Assets | 4 | 4 | 4 | 10 | 15 | 18 | 25 | 35 | 36 | 35 | |
| Curr. Assets | 1 | 1 | 1 | 2 | 43 | 48 | 61 | 70 | 73 | 90 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 6 | 5 | 4 | 12 | 58 | 65 | 86 | 107 | 109 | 125 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09 Rs. Cr. TTM |
| Net Sales | 6 | 2 | 0 | 1 | 76 | 94 | 106 | 133 | 125 | 140 | |
| Other Income | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | |
| Total Income | 7 | 2 | 0 | 2 | 77 | 95 | 107 | 135 | 126 | 141 | |
| Total Expenditure | -7 | -4 | -4 | -2 | -74 | -88 | -102 | -124 | -124 | -138 | |
| PBIDT | 0 | -1 | -3 | 0 | 3 | 7 | 5 | 11 | 2 | 4 | |
| Interest | 0 | 0 | -1 | 0 | -1 | -2 | -3 | -3 | -4 | -4 | |
| Depreciation | 0 | 0 | 0 | 0 | -1 | -1 | -2 | -2 | -3 | -3 | |
| Taxation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | |
| Exceptional Items | |||||||||||
| PAT | -1 | -2 | -4 | -1 | 2 | 4 | 1 | 5 | -4 | -2 | |
| Adjusted EPS | -1 | -2 | -5 | -1 | 1 | 3 | 0 | 1 | -1 | -1 |
| Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
| Cash Fr. Operatn. | 1 | 1 | 0 | -6 | -1 | -7 | -3 | 0 | 6 | 8 | |
| Cash Fr. Inv. | -1 | 0 | 0 | 0 | -6 | -2 | -2 | -9 | -14 | -1 | |
| Cash Fr. Finan. | -1 | 0 | 0 | 6 | 7 | 10 | 4 | 8 | 8 | -8 | |
| Net Change | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Cash & Cash Eqvt | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 |
|
Mon, 06 Feb 2023
Board Meeting Intimation for Intimation Of Board Meeting Of The Company And Continuation Of Closure Of Trading Window Kimia Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2023 inter alia to consider and approve This is to inform you that a meeting of the Board of Directors is scheduled to be held on Tuesday February 14 2023 at3:00 pm (IST) at the corporate office of the Company 974 9th Floor Aggarwal Millennium Tower-II NetajiSubhash Place Pitampura New Delhi-110034 to transact the following businesses amongst others:i. To consider and approve the un-audited financial results on a standalone basis of the Company forquarter and nine months ended December 31 2022 in accordance with Regulation 33 of SEBI (ListingObligation and Disclosure Requirements) Regulations 2015;ii. Any other matter as may be considered and transacted with permission of Board of Directors. |
|
Wed, 01 Feb 2023
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Pursuant to Regulation 39(3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015. The Company has received the intimation letter from our Registrar & Transfer Agent Beetal Financial Services Private Limited regarding the request received for issuance of duplicate share certificates the details of which are envisaged hereunder:S. No Name Folio No Certificate No. Distinctive Number Shares1. Saroj Devi Chindalia 1198 828 1316701-1317400 700 Pursuant to SEBI Circular No. SEBI/MIRSD/MIRSD_RTAMB/P/2022/8 dated January 25 2022 a letter of confirmation will be issued to the securities holder/ claimant upon completion of necessary procedures regarding duplicate share certificates. |
|
Mon, 30 Jan 2023
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Dear Sir/ Madam In reference to the earlier intimation dated 24.01.2023 Pursuant to Regulation 39(3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015. The Company has received the intimation letter from our Registrar & Transfer Agent Beetal Financial Computer Services Private Limited regarding the issuance of duplicate share certificates.The details of shareholders is envisaged as under:-NAME OF THE SHAREHOLDER FOLIO NO NEW CERTIFICATE NO DISTINCTIVE NOFROM-TO NO. OF SHARESRAM BABU GUPTA 11953 10842 2401801-2401900 100 |
| Wed, 08 Feb 2023 |
High Delivery Percentage
|
Higher Delivery Quantity
|
Higher Delivery Quantity and Percentage
|
Higher Trade Quantity
|
Higher Trade and Delivery Quantity
|
Equities
M.F.
Sectors